<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084734</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000365571</org_study_id>
    <secondary_id>RPCI-RPC-0209</secondary_id>
    <nct_id>NCT00084734</nct_id>
  </id_info>
  <brief_title>Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I and Pharmacokinetics Study of Docetaxel in Combination With Capecitabine and Cisplatin in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, capecitabine, and cisplatin, work&#xD;
      in different ways to stop tumor cells from dividing so they stop growing or die. Giving more&#xD;
      than one chemotherapy drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel,&#xD;
      capecitabine, and cisplatin in treating patients with metastatic or unresectable solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of docetaxel, cisplatin, and capecitabine in&#xD;
           patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and recommended phase II dose of this regimen in&#xD;
           these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the non-dose-limiting toxic effects associated with this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine any clinical activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive docetaxel IV over 30 minutes and cisplatin IV over 30 minutes on days 1 and&#xD;
      8 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of docetaxel, cisplatin, and capecitabine&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least&#xD;
      6 patients receive treatment at the MTD.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 21 patients will be accrued for this study within 1.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of docetaxel, cisplatin, and capecitabine in patients with advanced solid tumors.</measure>
    <time_frame>Every 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the non-dose-limiting toxic effects associated with this regimen in these patients</measure>
    <time_frame>Every 21 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">61</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Oral</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>IV</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor for which standard curative or&#xD;
             palliative measures do not exist or are no longer effective&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2.0 times upper limit of normal (ULN) AND alkaline phosphatase [AP] &lt;&#xD;
             ULN OR&#xD;
&#xD;
          -  AP ≤ 4 times ULN AND AST and ALT &lt; ULN&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to ingest oral medications&#xD;
&#xD;
          -  No allergy attributed to study drugs, compounds of similar chemical or biological&#xD;
             composition, drugs formulated in polysorbate 80, or other agents used in this study&#xD;
&#xD;
          -  No inner ear auditory toxicity ≥ grade 2&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No immunodeficiency&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent growth factors (sargramostim [GM-CSF] or filgrastim [G-CSF])&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents unless approved by the principal&#xD;
             investigator and medical monitor&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwan Fakih, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

